McGrath: Montana Settles with OxyContin Manufacturer
HELENA – Attorney General Mike McGrath said today that Montana and 25 other states have reached a settlement with drug company Purdue Pharma regarding the narcotic pain medication OxyContin.
The multi-state agreement resolves concerns that Purdue had engaged in extensive “off-label” marketing of OxyContin, promoting the drug for purposes other than its approved uses. The settling states also contended that Purdue failed to disclose the drug’s potential for abuse and addiction.
McGrath said that Montana’s share of the settlement is $500,000. The total settlement to the states is $19.5 million.
Under the terms of the settlement, Purdue is prohibited from:
- marketing and promoting OxyContin in a way that is inconsistent with the approved uses for the drug;
- marketing or promoting OxyContin for off-label purposes; and
- awarding bonuses to sales representatives that are based exclusively on the volume of OxyContin sales.
The settlement also requires Purdue to maintain an abuse and diversion-detection program to help detect so-called “problem prescribing” and requires Purdue sales representatives to inform health care providers about OxyContin and its potential for abuse.
“This case is another example of a company misrepresenting the risks associated with its product,” McGrath said. “Consumers and their health care providers deserve better.”